Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 555Gynecologic 25Gastrointestinal 20Thoracic 18Genitourinary 18Dermatologic 18Lymphoid 10CNS 9Sarcoma 8Plasma cell 8Other hematologic neoplasm 7Head & Neck 5Myeloid 3Other solid neoplasm 2NET 2Endocrine 2Other 1Classical hematology 1

Conditions

Neuroendocrine Tumors 4Breast Neoplasms 2Uveal Melanoma 1Urogenital Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Pheochromocytoma 1Paraganglioma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Multiple Myeloma 1Microsatellite Instability 1Mesothelioma 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Adrenocortical Carcinoma 1Adenoma, Islet Cell 1Adenocarcinoma of Lung 1

Interventions

Fluorodeoxyglucose F18 3Magnetic Resonance Spectroscopy 2Cyclophosphamide 2tivozanib 1romidepsin 1pembrolizumab 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1gadobutrol 1gadobenic acid 1fludarabine phosphate 1fludarabine 1entrectinib 1atezolizumab 1alectinib 1aldesleukin 1Specimen Handling 1Quality of Life 1Patient Reported Outcome Measures 1Neuropsychological Tests 1Molecular Diagnostic Techniques 1Lactones 1Interleukin-13 1Immunotherapy 1FAPI-46 1Drug Therapy 1Depsipeptides 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × Cyclophosphamide × NET × Clear all
NCT03412877 2026-05-22

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
285 enrolled
BreastEndocrineGynecologicNETPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Stanford University

Phase 1 Recruiting
18 enrolled
BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡